Most material SEC filings — October 15, 2026

Greenlane Holdings, Inc. filed an 8-K on October 15, 2026, reporting Item 1.03 (Bankruptcy or Receivership) for the period ending October 9, 2026. The filing does not provide specific details about the bankruptcy status, counterparties, amounts, or timeline within the available text excerpt. Additional detail would require accessing the complete 8-K document content.

On October 9, 2026, Innovative Eyewear Inc (market cap ~$7.0M) filed an 8-K disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has failed to meet exchange listing requirements. No specific remediation plan, timeline, or financial details are disclosed in the header materials provided.

Proofpoint, Inc. agreed to acquire Varonis Systems, Inc. in an all-cash merger with merger consideration of $49.75 per share, valuing the company at approximately $5.73 billion based on 115.3 million shares outstanding as of October 6, 2026. The merger is supported by Thoma Bravo funds' equity commitment and debt financing commitments. The transaction is subject to customary closing conditions including regulatory approvals under antitrust laws, and is expected to close during the Marketing Period or by the third business day thereafter.

Cenntro Inc. (market cap ~$30.3M) entered into an at-the-market (ATM) sales agreement with Pacific Century Securities, LLC on October 9, 2026, authorizing issuance and sale of up to $100,000,000 in common stock. The Sales Agent will sell shares on Nasdaq at prevailing market prices, earning a 3.5% commission on gross proceeds. The company reimburses the Sales Agent up to $100,000 in expenses ($50,000 paid upfront, $50,000 due at first closing), plus up to $5,000 per representation date and $10,000 per prospectus 'refresh.' No shares have been sold as of this filing date; the agreement is effective immediately upon execution.

Cyngn Inc. received notice of delisting or failure to satisfy a continued listing rule or standard on October 14, 2026. The 8-K Item 3.01 indicates the company failed to meet Nasdaq or NYSE continued listing criteria. No specific financial metrics, remediation timeline, or transfer of listing details are disclosed in the filing excerpt provided.

Co-Diagnostics entered into a loan agreement with J.J. Astor Co. on October 9, 2026, borrowing $3.1M in two tranches ($2.1M initial, $1M additional 60 days later) with senior secured promissory notes of $2.835M and $1.35M respectively (factor rate 1.35×). 100% of ATM net proceeds (from ~$7.35M available capacity) flow to a blocked deposit account controlled by Astor, which distributes: first $1M to Astor, then 80% to Astor and 20% to company until weekly payments satisfied, then 25%/75% split until repaid. Maxim Group LLC (ATM agent) remits proceeds within 3 business days to the locked account.

On October 15, 2026, Penske Automotive Group (PAG) entered into a merger agreement with Motown Acquisition Corp., a special purpose vehicle backed by the Investor Group (Penske Truck Leasing Co./PC and Mitsui), for $212.00 per share in cash. The transaction values PAG at approximately $13.9 billion (65.66M shares × $212). Buyer is backed by debt and equity commitments; the deal is subject to PAG stockholder approval (majority of unaffiliated shares required) and regulatory clearances. Closing expected after satisfaction of conditions including antitrust review.

FMC revised Q3 2026 revenue guidance to $65–$125M (from prior expectations) with Adjusted EBITDA of negative $565–$510M. The company is implementing comprehensive commercial actions including price reductions on select products in Brazil, Argentina, US, and Canada, plus restructuring its US pricing model from high-gross/high-rebate to simplified net pricing. These actions carry an estimated $625–$675M revenue and EBITDA impact. FMC also flagged a potential material non-cash intangible asset impairment and indicated it will seek covenant modifications from lenders.

CCC Intelligent Solutions Holdings Inc. agreed to merge with Mozart Merger Sub (subsidiary of Mozart Parent LLC), backed by GTCR funds and Elliott Associates, at $7.75 per share in cash. The transaction values the company at approximately $4.57 billion (590.7M shares × $7.75). Financing includes equity commitments from GTCR Fund XIV/A LP, GTCR Fund XIV/C LP, GTCR Co-Invest XIV/A LP, GTCR Co-Invest XIV/B LP, Elliott Associates L.P., and Elliott International L.P., plus debt and preferred equity financing. The company will become a private subsidiary of Parent post-closing.

OpenWorld, Inc. (NASDAQ: OPNW) announced a non-binding term sheet with Meridian (led by former Tesla/SolarCity investor Josh Raffaelli) to establish a tokenized financing program of up to $1 billion. OpenWorld will serve as advisor, structuring agent, and services provider to finance and operate a distributed AI computing network powered by residential solar panels and Tesla Powerwall battery storage across approximately 10,000 homes initially. Initial test installations are scheduled for Q4 2026, with first commercial deployment targeted for Q1 2027. The agreement is explicitly non-binding and subject to due diligence, definitive documentation, and regulatory approval.

Evolution Metals Technologies received 13 of 57 containers of ULVAC magnet production equipment at its Pohang facility on October 15, 2026, with remaining 44 containers due by end of October. This equipment expansion is intended to increase annual magnet capacity from 1,000 metric tons to ~10,000 metric tons (~6,000 high-performance sintered), positioning EMT as largest rare earth magnet producer outside China ahead of January 1, 2027 DFARS deadline. Company reaffirms FY2027 revenue guidance of $400–460 million.

iPower AI LLC received a non-binding letter of intent from an unnamed customer for a five-year AI equipment services relationship. The deal contemplates managing an initial 48 computing units (generating $13.27M over five years) expanding to 396 units by end-2027 (generating $21.90M annualized). The LOI is explicitly non-binding; definitive agreement, final terms, and revenue realization remain uncertain.

OPKO Health, Inc. and BioReference Health, LLC are selling their clinical laboratory testing business (including the 4Kscore prostate cancer test) to Laboratory Corporation of America Holdings for a base purchase price of $722 million, plus contingent 4Kscore payments up to $150 million over ten years (15% of cash receipts above a threshold). The transaction includes a transition services agreement and multiple purchase price adjustments based on business revenue retention.

Jeffrey Tirman, who holds 26 million DVLT shares (approximately 54.7% of current market cap at ~$47.5M) through his family office Abri Capital Ltd., was appointed to Datavault AI's Board of Directors effective October 12, 2026. Tirman was designated by NYIAX in connection with the company's recently completed acquisition of NYIAX and brings 35+ years of investment management and corporate restructuring experience. No compensation details, board seat count, or specific transaction terms regarding the NYIAX acquisition are disclosed in this announcement.

ChronoScale (NASDAQ: CHRN, market cap ~$15.6M) reported Q1 FY2027 revenue of $41.5M (up 148% YoY from $16.7M) with net loss of $26.4M. Key developments: (1) secured 50 MW AI compute deployment with Microsoft; (2) entered strategic partnerships with Nutanix and Baseten Labs (~4 MW, completion Q1 2027); (3) completed sale of Legacy Ekso Business on Sept 30, 2026, exiting that segment; (4) received $328.2M in aggregate prepayments under existing customer contracts; (5) announced target of $1B annualized run-rate revenue by calendar Q3 2027. Cash position: $15.2M as of Aug 31, 2026.

Esquire Financial Holdings agreed to acquire Signature Bancorporation in an all-stock merger. Esquire will issue 3,446,992 shares at an exchange ratio of 2.671x (valued at $445.4M based on $129.22/share on July 31, 2026), creating $219.4M in goodwill. Pro forma combined assets reach $4.59B (89% increase) and pro forma Q1 2026 net income is $20.1M (64% increase), with $35.5M pretax merger costs estimated.

Aquestive announced the FDA accepted its NDA resubmission for Anaphylm (dibutepinephrine) sublingual film for anaphylaxis treatment as complete, classifying it as a Class 2 response with a PDUFA goal date of March 16, 2027. The resubmission was submitted September 16, 2026, following positive human factors and pharmacokinetic study results in August 2026 that addressed FDA's January 2026 Complete Response Letter concerns. Concurrently, the company remains on track to submit a Canadian New Drug Submission in Q4 2026.

Bank7 Corp. reported Q3 2026 net income of $10.2M ($1.06 diluted EPS) vs. $8.3M ($0.87) in Q2 2026, a 22.25% increase. Total assets grew 4.84% to $2.01B; total loans grew 2.22% to $1.63B. The company announced that Century Financial Services shareholders approved the merger (already received regulatory approvals), expected to close November 1, 2026, adding ~$1.2B in legacy deposits and bringing combined assets to ~$3.3B with projected 25%+ EPS accretion. Capital ratios remain strong: Tier 1 leverage 14.12%, CET1 15.17%, RBC 16.30%—all well above regulatory minimums.

Ocugen presented clinical progress on three modifier gene therapy programs: OCU400 (retinitis pigmentosa, 140 patients, Phase 3 enrollment complete, 1H 2027 topline expected, 2Q 2027 BLA target); OCU410ST (Stargardt disease, 51 patients, Phase 2/3 enrollment complete, 2027 topline/BLA target); OCU410 (geographic atrophy, Phase 3 initiated 3Q 2026 with 237 patients, 2028 topline/BLA target). Received Bahamas provisional approval for OCU400 expanded access program with potential $1-2M revenue per patient. Two out-licensing deals noted: Kwangdong (up to $180M+ milestones, 25% royalties on OCU400); Roots Pharma (up to $255M milestones, 22% royalties on OCU400).

Quantum Leap Energy (QLE), a wholly-owned subsidiary of ASP Isotopes Inc. (ASPI), signed a binding Heads of Agreement with South Africa's Nuclear Energy Corporation (Necsa) to establish a joint venture for High-Assay Low-Enriched Uranium (HALEU) production at Necsa's Pelindaba site. QLE holds ~80% ownership; Necsa holds ~20% and provides site access, nuclear safeguards, and regulatory support. The JV is supported by offtake agreements with TerraPower and prior regulatory approval from South Africa's Ministry of Electricity and Energy (July 2026); a test bench facility exists and infrastructure refurbishment is underway.

Vivos issued 12,000 shares of Series C Convertible Preferred Stock (stated value $12 million, conversion price $0.15/share) to SOD Sciences in exchange for: (1) an 11% fully diluted equity interest in SOD (2,907,338 SOD common shares based on 23.5M pre-closing fully diluted shares), and (2) a 50% undivided co-ownership interest in SOD's pseudohypoxia early-warning test IP. Vivos and SOD will split contribution margin 50/50 on test sales; Vivos retains 80% margin on its own product sales through SOD's channels (American Health Associates and Cleveland Clinic Weston). No cash paid. Closing expected October 15, 2026, subject to auditor concurrence, Series B holder consent, and Nasdaq notification.

SenesTech reported preliminary Q3 2026 revenue of $1.1 million, representing 40% sequential growth from Q2 2026 and 55% year-over-year growth from Q3 2025. This is the company's first quarter exceeding $1 million in revenue and marks its highest quarterly revenue in company history. Management attributes growth to e-commerce scaling, B2B traction, and expanding subscription revenue.

Gulf Resources, Inc. (NASDAQ: GURE) announced October 14, 2026 governmental approval from Shouguang Municipal Government to resume production at Factories No. 2 and No. 10 in China. The company expects test/trial production in Q4 2026 and revenue generation in H1 2027. Resumption would increase annual production capacity by more than 20% according to the company's 2025 10-K filing.

GNK Holdings LLC filed an amended Schedule 13D/A on October 15, 2026, indicating a change in beneficial ownership disclosure regarding Reliance Global Group, Inc. The filing includes a formal demand for a special meeting of shareholders and a demand to inspect shareholder records, both dated October 15, 2026. The specific share count, percentage ownership, or dollar amounts of the amendment are not disclosed in this cover page.

GNK Holdings LLC filed an amended Schedule 13D on October 15, 2026, demanding a special meeting of shareholders and inspection of shareholder records for Reliance Global Group, Inc. (market cap ~$5.3M). The filing includes formal demand letters dated October 15, 2026, but specific share counts, ownership percentages, and strategic intentions are not disclosed in this filing header/cover page.

Datavault AI amended its $25.03M convertible promissory note issued to Streeterville Capital (dated August 18, 2026) effective October 15, 2026. The amendment establishes a Nasdaq Floor Price of $0.0632 per share (20% of the Nasdaq Minimum Price at issuance) that caps downward conversion price adjustments. This protects the lender from excessive dilution but limits the company's flexibility in subsequent equity issuances.

Consolidated Water's U.S. subsidiary PERC Water Corporation signed a design-build agreement with City of Pismo Beach for the Central Coast Blue Advanced Water Purification Facility valued at $39,790,682. The contract covers design, construction, testing, training, and startup of a 750 acre-feet-per-year advanced water treatment facility with ultrafiltration, reverse osmosis, and UV oxidation systems. Project is expected to proceed over ~24 months with construction starting spring 2027.

Melar Acquisition Corp. I (NASDAQ: MACI, ~$168M market cap) is merging with Everli Global Inc., an Italian e-grocery marketplace founded in 2014. Everli operates in 60+ Italian provinces with 95+ retail partners (including all 13 largest grocers: Lidl, Coop, Conad, Carrefour, Esselunga), 1,150+ stores, 300,000+ products, and 1,000+ weekly active shoppers—using an asset-light model with no owned warehouses or delivery fleet. The combined entity will trade as Everli Global Holdings Inc. (ticker: EVRL) on Nasdaq. Registration statement filed October 2, 2026; definitive proxy statement mailed to shareholders September 28, 2026. No specific deal valuation, share count, or closing date disclosed in this press release.

Endovia Health Sciences filed an 8-K on 2026-10-15 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits). The filing contains no substantive disclosure of the agreement's terms, counterparty, dollar amounts, share counts, or business impact—only XBRL data files and metadata. The actual agreement details are not provided in the available filing text.

Alcoa reported Q3 2026 net income of $483M ($1.81/share) on $3.7B revenue. On October 15, 2026, South32 shareholders approved the AliGroup acquisition. Alcoa issued $2.6B in debt ($1.5B at 6.625% due 2034, $1.1B at 6.875% due 2036) to fund ~$3.1B cash consideration; transaction expected to close H1 2027. Separately, Alcoa entered definitive agreements to sell portions of Massena East site for up to $315M in potential proceeds.

SUNation Energy, Inc. amended its secured revolving line of credit agreement with MBB Energy, LLC, extending the Maturity Date from an unstated prior date to April 15, 2027. The amendment was executed October 15, 2026. No credit facility size, interest rate, or financial terms beyond the maturity extension are disclosed in this filing.

IB Acquisition Corp. scheduled its first annual stockholder meeting for December 16, 2026 (record date October 28, 2026), to be held virtually. The company stated the meeting is intended to regain compliance with Nasdaq Listing Rule 5620(a), as referenced in a prior Form 8-K filed October 6, 2026. Stockholder proposals must be received by October 26, 2026.

On October 14, 2026, FreightCar America terminated its stockholder rights plan (poison pill) effective immediately and entered into a voting/transfer restriction agreement with three Oaktree Capital funds (OC III LVS XII LP, OC III LVS XXVIII LP, OC III LFE II LP). The agreement restricts the Oaktree entities from transferring shares to any party that would become a >20% owner without Board approval; locks in a 20% triggering threshold for any future poison pill; and expires in four years or when Oaktree's ownership drops below 20%. No specific share count or ownership percentage disclosed for Oaktree in these exhibits, though the 20% threshold is material.

First Tracks Biotherapeutics sold 6,106,870 shares of common stock to institutional investors at $32.75/share, generating ~$200M in gross proceeds before placement agent fees. The private placement involved new and existing investors (Affinity Asset Advisors, First Light Asset Management, Sirenia Capital, TCGX, Trails Edge Capital, Vestal Point Capital, and mutual funds). Closing expected October 19, 2026; proceeds intended for general corporate purposes including clinical development of ANB033.

Mesabi Trust's Trustees declared no distribution for Q4 2026 (payable November), versus $0.34/unit year-ago. July 2026 royalty payments from Cleveland-Cliffs/Northshore Mining totaled $1,807,779, down 66% from $5,300,287 in July 2025; no bonus royalties were earned in either Q1 or Q2 2026 because iron ore prices fell below the $71.70/ton threshold. The Trust is also building reserves for pending arbitration and managing uncertainty around Cliffs' supply-chain restructuring.

United States Natural Gas Fund, LP amended its ISDA Master Agreement with Société Générale effective October 13, 2026. The amendment modifies the Total Net Assets (TNA) Decline Event trigger from an unspecified prior level to US$200M for UNG specifically (versus US$1.5B for other counterparties). This contractual change defines the threshold at which derivative positions may be subject to forced termination or collateral calls.

Loop Industries reduced its planned Infinite Loop India facility from an undisclosed larger capacity to 45 kilotonnes per annum (KTA) to lower capital requirements and accelerate development. Construction target is now end of 2028 with startup in 2029. A Special Committee (formed September 2026) is actively seeking financing alternatives (equity, debt, non-dilutive) for Loop's portion of the India JV. The company reported Q2 FY2027 net loss of $2.99M (improved from $3.20M YoY), with available liquidity of only $1.9M at August 31, 2026.

Director Troim Tor Olav (BORR) bought 750K shares (~$3.5M) on the open market (1.9% of holdings). Open-market insider purchase — historically a bullish signal.

Executive Officer de Oliveira Andre Luis Duarte (BBD) bought 64K shares (~$1.1M) on the open market (17% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Tether Global Investments Fund, S.I.C.A.F., S.A. (GOLD) bought 68K shares (~$2.7M) on the open market (15% of holdings). Open-market insider purchase — historically a bullish signal.

Third Point LLC and Daniel S. Loeb filed a joint Schedule 13D on October 15, 2026, disclosing share transactions in Strata Critical Medical. Between August 31 and October 13, 2026, Third Point Master Fund LP and Third Point Ultra Master Fund L.P. engaged in coordinated trading: selling 43,500 shares combined in August–September at $5.11–$5.66, then aggressively buying 126,511 shares in October 12–13 at $4.53–$4.55 as price declined. Net position increased materially; filing triggered by reaching 5% beneficial ownership threshold.

Colony Bankcorp (NYSE: CBAN, market cap ~$275M) and First Reliance Bancshares (OTCQX: FSRL, $1.1B assets) announced shareholder approval on October 15, 2026, of a previously announced merger agreement valued at approximately $163 million in stock and cash. First Reliance will be acquired 100%, with closing anticipated in Q4 2026. Post-close, Colony expects ~$5B total assets, $4B deposits, and $3.2B loans across Georgia, South Carolina, and Florida.

10% owner NIPPON LIFE INSURANCE CO (CRBG) bought 254K shares (~$8.8M) on the open market (0.2% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner Alexandria Venture Investments, LLC (TRXB) bought 1.3M shares (~$2.5M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

Chief Executive Officer Cha Albert (FLSC) bought 300K shares (~$3.0M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

Opus Genetics presented clinical data at Retina in Rio 2026 (October 15, 2026) for two investigational gene therapies for inherited retinal diseases. OPGx-BEST1 showed improved retinal sensitivity in 3 of 4 evaluable participants (75%) in low-dose Cohort 1 of a Phase 1/2 trial; high-dose Cohort 2 has completed enrollment with 11 participants. OPGx-LCA5 demonstrated sustained visual acuity improvements through 24 months in 3 adult participants and through 6 months in 3 pediatric participants in an ongoing Phase 1/2/3 trial; Phase 3 dosing initiation is expected in Q4 2026, with both the natural history and treatment cohorts fully enrolled. No specific financial figures, partnership counterparties, or equity transactions are disclosed in this 8-K filing.

Establishment Labs amended its Master Supply Agreement with NuSil Technology LLC, effective January 1, 2027. The contract term was extended from December 31, 2026 to December 31, 2031 (5-year extension). Key changes include: exclusive silicone sourcing obligation for implant shells/gels, payment terms shifted to Net 30 EOM, addition of joint IP governance clause, and a last-time buy provision allowing up to [redacted] months of inventory upon NuSil's change of control. Multiple pricing and product specifications remain redacted.

Venture Global entered into frame agreements with GE Vernova and Baker Hughes for up to 16 new 720 MW power island units (11.52 GW total capacity) to support expansion of behind-the-meter, grid-independent power generation. The agreement enables up to 10 GW of new compute/data center capacity at company-owned sites by end of 2034, with first purchase order expected by end of 2026. The expansion is staged and contingent on customer commitments; no dollar values disclosed.

ManpowerGroup's Board elected Becky Frankiewicz, currently President and Chief Strategy Officer, as Chief Executive Officer effective January 1, 2027. Jonas Prising, CEO since 2014, transitions to Executive Chair. Frankiewicz will be the fifth CEO in the company's ~80-year history and will join the Board. The transition follows planned succession planning and reflects continuity in leadership; no financial terms or severance details are disclosed.

Commercial Metals reported fiscal 2026 net earnings of $655.8M (vs. $84.7M prior year) and core EBITDA of $1.4B (up from $837.3M), with core EBITDA margin expanding 380 basis points to 14.5%. The company completed acquisitions of Concrete Pipe & Precast (CP&P) and Foley Products, contributing $212M annualized EBITDA to the precast platform (CSG segment). Net leverage adjusted for acquisitions stands at 1.9x, below the 2.0x target. Q4 FY2026 showed net earnings of $212.5M ($1.91/diluted share) and adjusted earnings of $233.6M ($2.09/share), with core EBITDA of $393.7M (+35.1% YoY). The company repurchased 383,333 shares ($26.7M) and declared a $0.20 quarterly dividend.